Epix Pharmaceuticals
Founded Year
2000Stage
Dead | DeadAbout Epix Pharmaceuticals
EPIX Pharmaceuticals, formed from the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, is a biopharmaceutical company focused on discovering, developing and commercializing pharmaceutical products through the use of technology to better diagnose, treat and manage patients.
Missing: Epix Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Epix Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Epix Pharmaceuticals Patents
Epix Pharmaceuticals has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/19/2008 | 12/20/2011 | G protein coupled receptors, Autoimmune diseases, Monoclonal antibodies, Inflammations, Immunology | Grant |
Application Date | 9/19/2008 |
|---|---|
Grant Date | 12/20/2011 |
Title | |
Related Topics | G protein coupled receptors, Autoimmune diseases, Monoclonal antibodies, Inflammations, Immunology |
Status | Grant |
Latest Epix Pharmaceuticals News
Nov 26, 2016
EPIX Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 21:50 EST 25 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » EPIX Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' EPIX Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by EPIX Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on EPIX Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by EPIX Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for EPIX Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about EPIX Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Epix Pharmaceuticals Frequently Asked Questions (FAQ)
When was Epix Pharmaceuticals founded?
Epix Pharmaceuticals was founded in 2000.
Where is Epix Pharmaceuticals's headquarters?
Epix Pharmaceuticals's headquarters is located at 4 Maguire Road, Lexington.
What is Epix Pharmaceuticals's latest funding round?
Epix Pharmaceuticals's latest funding round is Dead.
Who are the investors of Epix Pharmaceuticals?
Investors of Epix Pharmaceuticals include SRB Management, Prescott Group Capital Management, TD Asset Management, Westfield Capital Management, American International Group and 14 more.
Who are Epix Pharmaceuticals's competitors?
Competitors of Epix Pharmaceuticals include Sound Pharmaceuticals, Callisto Pharmaceuticals, Anadys Pharmaceuticals, Inspire Pharmaceuticals, Memory Pharmaceuticals and 10 more.
Compare Epix Pharmaceuticals to Competitors
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical products that target unmet medical needs in rheumatology and other specialty niche medical markets. The company's focus is on the company's biologic product candidate, Puricase (pegloticase) that has been developed for treatment-failure gout (TFG).
Janus Pharmaceuticals Inc. (Janus) is a specialty pharmaceutical company identifying, acquiring and aggressively developing topical prescription products for treatment of skin infections. Determined to be the "Dermal Alternative", Janus has already established a strong intellectual property portfolio for topical anti-infective compounds that would be rapidly commercialized through fast regulatory pathways. Led by an accomplished management team and board located in the US and Japan, Janus has trans-Pacific network and resources in the biopharmaceutical industry.
Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology platform.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.